Northern Trust Corp increased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 9.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 750,442 shares of the biopharmaceutical company’s stock after buying an additional 66,677 shares during the quarter. Northern Trust Corp’s holdings in Dynavax Technologies were worth $11,445,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the stock. WINTON GROUP Ltd bought a new stake in Dynavax Technologies during the first quarter worth about $199,000. Xact Kapitalforvaltning AB bought a new stake in Dynavax Technologies during the first quarter worth about $200,000. Tiverton Asset Management LLC bought a new stake in Dynavax Technologies during the second quarter worth about $184,000. Bank of Montreal Can grew its stake in Dynavax Technologies by 365.4% during the second quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 10,943 shares during the last quarter. Finally, LPL Financial LLC bought a new stake in Dynavax Technologies during the first quarter worth about $283,000. 81.48% of the stock is owned by hedge funds and other institutional investors.
DVAX opened at $12.09 on Friday. Dynavax Technologies Co. has a one year low of $9.63 and a one year high of $22.80. The company has a current ratio of 8.87, a quick ratio of 8.67 and a debt-to-equity ratio of 0.76. The company has a market cap of $756.69 million, a PE ratio of -6.99 and a beta of 0.61.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative net margin of 5,044.85% and a negative return on equity of 87.67%. The company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $3.16 million. During the same period last year, the company earned ($0.38) earnings per share. Dynavax Technologies’s revenue for the quarter was up 2822.0% compared to the same quarter last year. As a group, equities analysts anticipate that Dynavax Technologies Co. will post -2.49 EPS for the current fiscal year.
DVAX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, October 1st. BidaskClub cut shares of Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 18th. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Cowen reaffirmed a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, October 22nd. Finally, Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Dynavax Technologies has an average rating of “Hold” and a consensus price target of $28.00.
WARNING: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/10/northern-trust-corp-acquires-66677-shares-of-dynavax-technologies-co-dvax.html.
Dynavax Technologies Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Featured Article: What impact do institutional investors have on markets?
Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.